239 related articles for article (PubMed ID: 28720328)
1. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
Ibrahim MK; Eissa IH; Alesawy MS; Metwaly AM; Radwan MM; ElSohly MA
Bioorg Med Chem; 2017 Sep; 25(17):4723-4744. PubMed ID: 28720328
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists.
El-Zahabi MA; Elbendary ER; Bamanie FH; Radwan MF; Ghareib SA; Eissa IH
Bioorg Chem; 2019 Oct; 91():103115. PubMed ID: 31310882
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
Ibrahim MK; Eissa IH; Abdallah AE; Metwaly AM; Radwan MM; ElSohly MA
Bioorg Med Chem; 2017 Feb; 25(4):1496-1513. PubMed ID: 28117121
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists.
El-Zahabi MA; Bamanie FH; Ghareeb S; Alshaeri HK; Alasmari MM; Moustafa M; Al-Marzooki Z; Zayed MF
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077003
[TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
6. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
8. Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.
Zhang X; Liu H; Sun B; Sun Y; Zhong W; Liu Y; Chen S; Ling H; Zhou L; Jing X; Qin Y; Xiao T; Sun T; Zhou H; Yang C
Sci Rep; 2016 Nov; 6():37323. PubMed ID: 27853282
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
10. In Silico Design, Synthesis and Evaluation of Novel Series of Benzothiazole- Based Pyrazolidinediones as Potent Hypoglycemic Agents.
Haroun M
Med Chem; 2020; 16(6):812-825. PubMed ID: 31880249
[TBL] [Abstract][Full Text] [Related]
11. Isolated mangiferin and naringenin exert antidiabetic effect via PPAR
Singh AK; Raj V; Keshari AK; Rai A; Kumar P; Rawat A; Maity B; Kumar D; Prakash A; De A; Samanta A; Bhattacharya B; Saha S
Chem Biol Interact; 2018 Jan; 280():33-44. PubMed ID: 29223569
[TBL] [Abstract][Full Text] [Related]
12. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
[TBL] [Abstract][Full Text] [Related]
14. Novel Hybrids of Pyrazolidinedione and Benzothiazole as TZD Analogues. Rationale Design, Synthesis and In Vivo Anti-Diabetic Evaluation.
Haroun M
Med Chem; 2019; 15(6):624-633. PubMed ID: 31113352
[TBL] [Abstract][Full Text] [Related]
15. Docking, synthesis and anti-diabetic activity of novel sulfonylhydrazone derivatives designed as PPAR-gamma agonists.
Zapata-Sudo G; Lima LM; Pereira SL; Trachez MM; da Costa FP; Souza BJ; Monteiro CE; Romeiro NC; D'Andrea ÉD; Sudo RT; Barreiro EJ
Curr Top Med Chem; 2012; 12(19):2037-48. PubMed ID: 23167793
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents.
Kumar A; Maurya RA; Sharma S; Ahmad P; Singh AB; Tamrakar AK; Srivastava AK
Bioorg Med Chem; 2009 Jul; 17(14):5285-92. PubMed ID: 19500993
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
20. (S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
Morishita K; Miike T; Takeda S; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
Chem Pharm Bull (Tokyo); 2019; 67(11):1211-1224. PubMed ID: 31685749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
